A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing Retinoschisin (rAAV2tYF-CB-hRS1) in Patients With X-linked Retinoschisis

Trial Profile

A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing Retinoschisin (rAAV2tYF-CB-hRS1) in Patients With X-linked Retinoschisis

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 20 Nov 2017

At a glance

  • Drugs AAV RS1 (Primary)
  • Indications Retinoschisis
  • Focus Adverse reactions
  • Sponsors Applied Genetic Technologies Corporation
  • Most Recent Events

    • 07 Nov 2017 According to an AGTC media release, to date, the company has completed enrollment of 12 patients in the first four groups which completes the dose escalation phase of the trial.
    • 13 Sep 2017 According to an AGTC media release, safety and tolearability results were presented at the Macula Society Annual Meeting.
    • 13 Sep 2017 According to an AGTC media release, the company has enrolled 17 adults and one child in the trial across all groups as of 13 Sep 2017 and expects to fully enroll expansion group in the first quarter of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top